AA Financial Advisors LLC Lowers Position in Astrazeneca Plc $AZN

AA Financial Advisors LLC lessened its stake in Astrazeneca Plc (NYSE:AZN) by 31.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,055 shares of the company’s stock after selling 2,774 shares during the quarter. AA Financial Advisors LLC’s holdings in Astrazeneca were worth $557,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of AZN. Bank of America Corp DE lifted its stake in Astrazeneca by 4.7% during the 3rd quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock valued at $2,503,614,000 after acquiring an additional 1,461,786 shares in the last quarter. Fisher Asset Management LLC grew its stake in shares of Astrazeneca by 2.3% in the 3rd quarter. Fisher Asset Management LLC now owns 21,162,724 shares of the company’s stock worth $1,623,604,000 after acquiring an additional 466,745 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Astrazeneca by 9.4% in the third quarter. Dimensional Fund Advisors LP now owns 6,805,896 shares of the company’s stock valued at $521,517,000 after purchasing an additional 582,183 shares during the last quarter. Holocene Advisors LP raised its holdings in shares of Astrazeneca by 41.8% in the third quarter. Holocene Advisors LP now owns 6,129,194 shares of the company’s stock valued at $470,232,000 after purchasing an additional 1,807,565 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its position in shares of Astrazeneca by 13.1% during the third quarter. Ameriprise Financial Inc. now owns 5,707,561 shares of the company’s stock valued at $438,342,000 after purchasing an additional 660,569 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Astrazeneca Stock Performance

AZN opened at $188.57 on Monday. Astrazeneca Plc has a fifty-two week low of $122.48 and a fifty-two week high of $212.71. The company has a debt-to-equity ratio of 0.51, a current ratio of 0.94 and a quick ratio of 0.72. The stock has a market cap of $292.45 billion, a P/E ratio of 32.48, a P/E/G ratio of 1.42 and a beta of 0.32.

Astrazeneca Dividend Announcement

The business also recently announced a dividend, which was paid on Monday, March 23rd. Stockholders of record on Friday, February 20th were given a dividend of $1.595 per share. This represents a dividend yield of 156.0%. The ex-dividend date of this dividend was Friday, February 20th. Astrazeneca’s dividend payout ratio is currently 66.26%.

Wall Street Analysts Forecast Growth

AZN has been the topic of several analyst reports. TD Cowen restated a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Morgan Stanley reissued an “overweight” rating and set a $103.00 target price on shares of Astrazeneca in a research report on Wednesday, December 3rd. HSBC restated a “buy” rating and issued a $108.00 target price on shares of Astrazeneca in a research note on Wednesday, December 10th. Guggenheim reaffirmed a “buy” rating on shares of Astrazeneca in a report on Wednesday, December 3rd. Finally, Citigroup assumed coverage on Astrazeneca in a research report on Tuesday, January 27th. They set a “buy” rating for the company. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Astrazeneca presently has a consensus rating of “Moderate Buy” and a consensus price target of $95.75.

More Astrazeneca News

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: Late‑stage trial win — Tozorakimab met primary goals in two pivotal trials, reducing chronic obstructive pulmonary disease flare‑ups versus placebo; the surprise positive readout is driving optimism about near‑term commercialization potential and pipeline momentum. AstraZeneca stock jumps 4% after surprise trial win for lung disease drug where rivals have failed
• Positive Sentiment: Regulatory and commercial implications — Reuters and other outlets highlight the meaningful reduction in flare‑ups and the significance of a successful phase III outcome for a disease area where competitors have struggled, which increases the drug’s value on AstraZeneca’s roadmap. AstraZeneca drug reduces COPD flare ups in late-stage trials
• Positive Sentiment: Clinical confirmation across endpoints — The Wall Street Journal and other reports emphasize that the trials hit their primary endpoints by lowering symptom worsening rates, reinforcing confidence in the data’s robustness and the potential for label and payer discussions. AstraZeneca Lung Disease Drug Candidate Hits Goals in Late-Stage Trials
• Neutral Sentiment: Stock movement vs. market — Coverage notes AZN advanced while broader markets were down, indicating the move is company‑specific (trial news/pipeline) rather than market driven. Astrazeneca (AZN) Advances While Market Declines: Some Information for Investors
• Neutral Sentiment: Analyst positioning — AstraZeneca has a consensus analyst rating of “Moderate Buy,” which supports the stock’s upside but does not by itself explain today’s move; analyst views may follow as investigators and investors digest full data and commercial assumptions. Astrazeneca Plc (NYSE:AZN) Receives Consensus Rating of “Moderate Buy” from Analysts

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.